Dr. Nam Q. Bui, MD
Medical Oncology (Medical Oncology Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 197
Licensed in California since 2012, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A122472 (first issued 2012; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
- Stanford Health Care Tri-Valley Pleasanton, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 197
- Services billed
- 603
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 231 | 91 |
| Established patient office or other outpatient visit, 30-39 minutes | 113 | 76 |
| Established patient office or other outpatient visit, 20-29 minutes | 102 | 71 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 42 | 26 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 33 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imatinib Mesylate | 80 |
| Ondansetron Hcl Other prescribers in Stanford, CA | 63 |
| Eliquis (apixaban) Other prescribers in Stanford, CA | 46 |
| Ibrance (palbociclib) | 35 |
| Prednisone Other prescribers in Stanford, CA | 26 |
| Sunitinib Malate | 23 |
| Oxycodone Hcl Other prescribers in Stanford, CA | 23 |
| Pazopanib Hcl | 22 |
| Prochlorperazine Maleate Other prescribers in Stanford, CA | 21 |
| Lorazepam Other prescribers in Stanford, CA | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $1,354 in total to this clinician.
| Deciphera Pharmaceuticals Inc. | $1,354 |
|---|
| Compensation for services other than consulting (speaking, faculty) | $1,200 |
|---|---|
| Food and Beverage | $154 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) ROMVIMZA · ONCOLOGY | $600 |
| Deciphera Pharmaceuticals Inc. Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $42,346 in research payments for these studies, mostly to the institutions running them.
- NIR-DT-301
Springworks Therapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.